Regor Pharmaceuticals Inc. has divulged phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Marjorie Zettler, PhD, MPH is Executive Director of Clinical Science at Regor Pharmaceuticals, Inc. and a 2022 Woman Worth Watching® in STEM. An award-winning industry veteran with two decades ...